FDA Will Require Early Assessment of New Targeted Agents That May Be Used in Pediatric Cancers
FDA Approvals, News & Updates, Web Exclusives
On December 12, 2019, the FDA issued draft guidance to implement amendments to the Federal Food, Drug, and Cosmetic (FD&C) Act that will facilitate early assessment of studies of molecularly targeted oncology drugs that may be effective in the treatment of pediatric cancers.
The guidance document was issued in advance of original new drug applications (NDAs) and biologics license applications (BLAs) that the FDA expects to receive on or after August 18, 2020, the date that the provisions of the amendment will become effective.
Titled âFDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C ActâGuidance for Industry,â the document is designed to provide information to pharmaceutical companies, clinical investigators, and institutional review boards ahead of planning their studies of molecularly targeted oncology drugs, with stipulations for early planning for pediatric evaluation of products that have the potential to treat this patient population.
âSpecifically, if an original NDA or BLA is for a new active ingredient, and the drug that is the subject of the application is intended for treatment of an adult cancer and directed at a molecular target the FDA determines to be substantially relevant to the growth or progression of a pediatric cancer, reports on the required molecularly targeted pediatric cancer investigation must be submitted with the marketing application, unless this requirement is waived or deferred,â the FDA noted in a press release.
According to Adm. Brett P. Giroir, MD, Acting FDA Commissioner, the agency anticipates that the new amendments âwill facilitate early pediatric assessment of certain targeted cancer drugs and accelerate the development of new, safe, and effective therapies for pediatric patients.â
The FDA will issue the final version of the guidance in 2020 and invites comments on the draft, preferably by February 11, 2020.
âWhen it comes to medical product innovation, children must always remain front-of-mind, particularly those with dire needs. It is important to deliver promising new therapies as quickly as possible, while still ensuring the utmost safety,â Dr Giroir added.
2021 Year in Review: Advances in Dual Immunotherapy Cancer Treatments
Dual immunotherapy for cancer has been one of the most successful modes of treatment researched and developed in recent years, with many new studies having been completed this past year. Immunotherapy has been used in the past for oncological treatments with monotherapy and in combination with chemotherapy; these new studies [ Read More ]
Asthma and the Role of Managed Care Pharmacy
Managed care organizations (MCOs) allocate resources to improve the quality of asthma care while controlling asthma-related drug costs. MCOs that are accredited by the National Committee for Quality Assurance (NCQA) focus on Healthcare Effectiveness Data and Information Set (HEDIS) measures to develop management strategies for drugs. NCQA-accredited MCOs strive to [ Read More ]